The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis Ilaris for use in acute gouty arthritis patients who are not suitable for current treatments. The only ...
Tags: Medicinal Products, therapies, treatments
Bicycle Therapeutics,had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform. Current investors, Atlas Venture, Novartis Venture Fund, SR One ...
Tags: Bicycle, drug discovery funding, pharma, healthcare
Aileron Therapeutics has secured the second tranche in its series D financing, meaning the overall total has now reached $42 million (pound 26 million). This payment followed the successful progression of the company's ALRN-5281 lead ...
Dendreon Corporation has sold its immunotherapy manufacturing facility (IMF) in Morris Plains, New Jersey, US, to Novartis Pharmaceuticals for $43m. In early 2012, Dendreon had decided to bring down Provenge production at the facility as ...
Tags: Novartis, Dendreon immunotherapy, manufacturing facility, Medicine
2012 was the year of big data.2011 had been a good year for the hyped concept,too,and 2013 is more than likely to see a continued glut of big data discourse in the IT market. But there are other themes in this collection of top 10 ...
Tags: big data, IT market, information management stories, data warehouse
The USFDA has approved Novartis' Signifor (pasireotide) injection to treat Cushing's disease, an endocrine disorder. The only approved pituitary-directed therapy in the US, for the patients who are not suitable for pituitary surgery, ...
Tags: USFDA, Cushing's disease, clinical treatment
Novartis, Incyte's strategic collaborator, has received the European Commission approval for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor to treat patients with myelofibrosis. The oral JAK 1 and JAK 2 inhibitor ...
Mylan Pharmaceuticals has gained final FDA approval for its abbreviated new drug application (ANDA) for Fluvastatin Capsules USP, 20mg and 40mg, and began shipment of the product. The product, a generic version of Novartis' Lescol ...
Novartis has obtained the US Food and Drug Administration (FDA) approval for a new 13.3 mg/24 h dosage strength of its Exelon Patch (rivastigmine transdermal system), designed to treat patients with mild to moderate Alzheimer's disease. ...
Tags: Alzheimer's disease, Novartis Pharmaceuticals, Exelon Patch
Sosei Group Corporation,Japan, has received a positive opinion for its Seebri Breezhaler (glycopyrronium bromide/NVA237),a type of bronchodilator, from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). ...
Tags: Seebri Breezhaler, bronchodilator, CHMP, Positive Chmp Opinion
Novartis has planned to update the Rasilez's labelling to include contraindications against combined use with a number of products. The company will follow the advice of the EMA's Committee for Medicinal Products for Human Use (CHMP) in ...
Tags: Novartis, CHMP, Rasilez's labelling
Bexsero, Novartis' Meningococcal Group B Vaccine, has won a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP opinion indicates the use of the broad coverage vaccine in ...
Novartis' Exjade has received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Exjade is used to treat chronic iron overload requiring chelation therapy when ...
Tags: Medicinal Products, iron overload, CHMP recommendation
Teva, a provider of generic pharmaceutical drugs, has introduced Rivastigmine capsules for generic prescription. Rivastigmine is generic equivalent to Novartis' Exelon capsules. Rivastigmine is indicated for use in the symptomatic ...
Tags: Teva, rivastigmine, Novartis'Exelon capsules
Novartis has announced a label change for Gilenya in the US, to include cardiovascular monitoring, while the EMA has called for similar changes in Europe. The US label changes are the result of discussions with the FDA, following ...